FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda has given "May Apply" recommendation to Medicamen Organics IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 1 | 0 | 0 | 0 |
% | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | May Apply |
[Dilip Davda] The company is operating in a highly competitive and fragmented segment of Pharma products. It posted average financial performance for the reported periods with boosted bottom line for FY24. Based on FY24 earnings, the issue appears fully priced. Well-informed investors may park moderate funds for the long term rewards. Read detail review...
Medicamen Organics Limited peer comparison with similar listed entities. (As on March 31, 2024)
Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
---|---|---|---|---|---|---|---|
Medicamen Organics Limited | 3.18 | 3.18 | 17.66 | 15.83 | 1.93 | ||
Brooks Laboratories Ltd. | -12.57 | -12.57 | 30.10 | 10.60 | -28.26 | 4.43 | |
Cian Healthcare Ltd | 0.43 | 0.43 | 22.40 | 53.84 | 1.75 | 1.03 | |
Zenotech Laboratories Ltd. | 1.90 | 1.90 | 14.20 | 38.76 | 14.08 | 5.19 |
Notes:
Medicamen Organics IPO Reviews, analysis and views by popular members. Read Medicamen Organics Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 0 |
% |
Member | Review |
---|---|
No recommendation found. Be the first to post the
recommendation. |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|